Abstract: OBJECTIVE To evaluate the efficacy and safety of high maintenance dose of teicoplanin in treatment of methicillin-resistant Staphylococcus aureus (MRSA) pulmonary infection so as to provide objective basis for clinical treatment of the infection. METHODS A total of 96 patients with MRSA pulmonary infection who were treated in the hospital from Jan 2015 to Dec 2016 were recruited as the study objects and divided into the experimental group and the control group, with 48 cases in each group. The control group was given the routine maintenance dose of teicoplanin (400mg/d), while the experimental group was treated with high maintenance dose of teicoplanin (600mg/d). The curative effect indexes and trough plasma concentration (Cmin) of teicoplanin were observed and compared between the two groups of patients; the clearance effect of pathogens, clinical therapeutic effect and adverse reactions during the treatment were observed. RESULTS The curative effect indexes of the experimental group were better than those of the control group(P<0.001), and the Cmin of teicoplanin of the experimental group was higher than that of the control group(P<0.001). The clearance effect of pathogens of the experimental group was better than that of the control group (P<0.001). There were no significant differences in the adverse reactions between the two groups of patients. CONCLUSION The high maintenance dose of teicoplanin may boost the curative effect of the patients with MRSA pulmonary infection, accelerate the recovery of clinical symptoms, raise the clearance rate of pathogens and maintain high plasma concentration without increasing the incidence of adverse reactions, with the safety high.